{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T01:39:21Z","timestamp":1711071561467},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1697","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the sodium\/hydrogen exchanger 3 (NHE3) inhibitor tenapanor (Xphozah \u2013 Ardelyx) to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy when phosphate binders are ineffective or as monotherapy when phosphate binders cannot be tolerated. Tenapanor is the first NHE3 inhibitor to be approved in the US for hyperphosphatemia. It was previously approved as Ibsrela to treat irritable bowel syndrome with constipation (IBS-C).<\/jats:p>","DOI":"10.58347\/tml.2024.1697b","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:47:33Z","timestamp":1711046853000},"page":"38-39","source":"Crossref","is-referenced-by-count":0,"title":["Tenapanor (Xphozah) for Hyperphosphatemia in Chronic Kidney Disease"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,3,4]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T18:47:43Z","timestamp":1711046863000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1697b"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":0,"journal-issue":{"issue":"1697","published-online":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1697b","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}